Natural Alternatives International, Inc. income statement NAII

Annual Quarterly

In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, Natural Alternatives International, Inc. reported revenue of $34.5 million, up 1.9% from the same quarter a year earlier. It recorded a net loss of $13.5 million. The operating loss came to $13.2 million, an operating margin of -38.2%. Diluted earnings per share were -$2.23.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	Q4 FY2026 Jun 30, 2026	Q3 FY2026 Mar 31, 2026	Q2 FY2026 Dec 31, 2025	Q1 FY2026 Sep 30, 2025	Q4 FY2025 Jun 30, 2025	Q3 FY2025 Mar 31, 2025	Q2 FY2025 Dec 31, 2024	Q1 FY2025 Sep 30, 2024
Revenue	35 +1.9%	35 +23.3%	35 +2.1%	38 +13.8%	34 +14.8%	29 +14.4%	34 +35.2%	33 -2.4%
Cost of revenue	33 +8.1%	35 +30.3%	32 -0.3%	33 +7.9%	30 +8.1%	27 +16.1%	32 +30.6%	31 +0.2%
Gross profit	2 -51.2%	0 -79.0%	2 +49.3%	4 +94.6%	4 +149.1%	2 -5.0%	2 +331.3%	2 -28.0%
Selling, general and administrative	—	4 +12.0%	4 -2.5%	4 +0.4%	—	4 +1.3%	4 +14.1%	4 +11.2%
Operating income	-13 -577.7%	-4 -91.1%	-2 +33.6%	0 +115.5%	-2 +23.0%	-2 -7.6%	-3 +20.9%	-2 -237.5%
Interest income	0 -53.5%	0 -100.0%	0 -100.0%	0 -9.1%	0 -43.4%	0 -35.4%	0 +215.4%	0 +266.7%
Other non-operating income (expense)	-0 -111.1%	-0 -12.5%	-0 -2033.3%	0 +1500.0%	0 +118.8%	-0 -500.0%	-0 +85.7%	-0 -104.8%
Other income (expense)	-0 +63.5%	-0 +57.7%	-0 -460.5%	-0 +16.3%	-1 -241.8%	-1 -3287.5%	-0 +73.0%	-1 -69.7%
Pretax income	-13 -378.7%	-4 -60.6%	-2 +18.7%	-0 +91.8%	-3 -1.4%	-3 -34.2%	-3 +25.2%	-2 -173.0%
Income tax	0 -99.0%	0 +114.9%	0 +133.2%	0 +121.3%	4 +584.8%	-0 -16.9%	-1 +11.3%	-0 -128.0%
Net income	-14 -87.6%	-4 -97.2%	-3 -16.5%	-0 +85.3%	-7 -285.1%	-2 -38.5%	-2 +28.6%	-2 -185.2%
Basic EPS	-2.23 -85.5%	-0.72 -94.6%	-0.42 -13.5%	-0.05 +84.8%	-1.20 -279.5%	-0.37 -37.0%	-0.37 +28.8%	-0.33 -175.0%
Diluted EPS	-2.23 -85.5%	-0.72 -94.6%	-0.42 -13.5%	-0.05 +84.8%	-1.20 -279.5%	-0.37 -37.0%	-0.37 +28.8%	-0.33 -175.0%
Weighted average shares, basic	6 +1.1%	6 +1.4%	6 +1.5%	6 +1.5%	6 +1.5%	6 +1.3%	6 +1.2%	6 +1.2%
Weighted average shares, diluted	6 +1.1%	6 +1.4%	6 +1.5%	6 +1.5%	6 +1.5%	6 +1.3%	6 +1.2%	6 +1.2%
Other measures
Depreciation and amortization	1 +2.0%	1 +4.8%	1 +2.8%	1 +3.5%	1 -4.0%	1 +3.7%	1 -4.9%	1 -1.8%
EBITDA	-12 -1429.6%	-3 -193.4%	-1 +58.6%	1 +304.5%	-1 +40.5%	-1 -12.5%	-2 +29.1%	-1 -217.4%
Margins
Gross margin	5.00%	1.08%	7.16%	11.65%	10.44%	6.35%	4.90%	6.81%
Operating margin	-38.18%	-11.31%	-5.31%	0.75%	-5.74%	-7.30%	-8.16%	-5.54%
Pretax margin	-39.10%	-11.96%	-6.69%	-0.53%	-8.32%	-9.18%	-8.41%	-7.28%
Profit margin	-39.24%	-12.15%	-7.34%	-0.77%	-21.31%	-7.60%	-6.43%	-5.98%
EBITDA margin	-34.75%	-7.95%	-1.96%	3.84%	-2.32%	-3.34%	-4.83%	-2.14%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: NAII (Nasdaq)
Fiscal year ends: June 30
Incorporated in: DE
Headquarters: Carlsbad, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 787253

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.